Ocular Therapeutix (OCUL) – Research Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Ocular Therapeutix (NASDAQ: OCUL) recently:

• 12/9/2025 – Ocular Therapeutix had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
• 12/8/2025 – Ocular Therapeutix had its price target raised by analysts at HC Wainwright from $19.00 to $21.00. They now have a “buy” rating on the stock.
• 12/8/2025 – Ocular Therapeutix had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
• 12/6/2025 – Ocular Therapeutix was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/25/2025 – Ocular Therapeutix had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
• 11/24/2025 – Ocular Therapeutix was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/16/2025 – Ocular Therapeutix was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/8/2025 – Ocular Therapeutix was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/5/2025 – Ocular Therapeutix had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada.
• 11/5/2025 – Ocular Therapeutix had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
• 10/30/2025 – Ocular Therapeutix had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 10/30/2025 – Ocular Therapeutix had its price target raised by analysts at TD Cowen from $14.00 to $20.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other Ocular Therapeutix news, insider Jeffrey S. Heier sold 10,502 shares of the stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $11.04, for a total value of $115,942.08. Following the transaction, the insider directly owned 249,409 shares in the company, valued at approximately $2,753,475.36. This trade represents a 4.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Todd Anderman sold 11,132 shares of the company’s stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $12.34, for a total value of $137,368.88. Following the completion of the sale, the insider owned 87,568 shares of the company’s stock, valued at $1,080,589.12. This trade represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 31,287 shares of company stock valued at $359,784 over the last 90 days. Company insiders own 2.30% of the company’s stock.

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.